MARKET

DRNA

DRNA

Dicerna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.23
+0.30
+1.67%
Opening 10:11 03/31 EDT
OPEN
17.79
PREV CLOSE
17.93
HIGH
18.38
LOW
16.79
VOLUME
25.09K
TURNOVER
--
52 WEEK HIGH
27.68
52 WEEK LOW
10.70
MARKET CAP
1.34B
P/E (TTM)
-10.3609
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of DRNA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DRNA stock price target is 33.00 with a high estimate of 50.00 and a low estimate of 25.00.

EPS

DRNA News

More
  • Dicerna Addresses Business Continuity in Response to COVID-19 Pandemic
  • Business Wire · 4d ago
  • Selloff creating bargains in healthcare - Baird
  • Seeking Alpha - Article · 5d ago
  • Stocks Flashing Renewed Technical Strength: Dicerna Pharmaceuticals
  • Investor's Business Daily · 03/23 23:23
  • The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
  • Benzinga · 03/19 12:37

Industry

Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.37%

Hot Stocks

Symbol
Price
%Change

About DRNA

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.
More

Webull offers kinds of Dicerna Pharmaceuticals Inc stock information, including NASDAQ:DRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRNA stock news, and many more online research tools to help you make informed decisions.